| Drug General Information |
| Drug ID |
D0K3EW
|
| Former ID |
DNC011024
|
| Drug Name |
6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H21Cl2NO
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Serotonergic synapsehsa00140:Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
XenobioticsR-HSA-211981:Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tamoxifen metabolism
|
|
Oxidation by Cytochrome P450
|
|
Vitamin D Receptor Pathway
|
|
Aripiprazole Metabolic Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine MetabolismWP702:Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tryptophan metabolism
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2010 Jul 8;53(13):4989-5001.6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. |
|---|
